Vascular Biogenics Prices its Initial Public Offering

Reston – November 5, 2014 – Cooley advised the underwriters on Vascular Biogenics Ltd.'s initial public offering. Vascular Biogenics is an Israel-based clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. The company now trades on The NASDAQ Global Stock Market under the symbol "VBLT."

Deutsche Bank Securities acted as the sole book-running manager for the offering. JMP Securities and Oppenheimer & Co. acted as co-managers for the offering.

The Cooley corporate and securities team advising the underwriters was comprised of partners Brent Siler and Darren DeStefano and associates Hosea Chang and Mark Ballantyne.

Critical support was provided by partner Natasha Leskovsek (health care and life sciences regulatory); partner Bonnie Weiss McLeod and associates Fraser Brown and Sandhya Deo (intellectual property); and partner Susan Philpot (tax).

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has 800 lawyers across 11 offices in the United States and China.

Related Contacts
Susan Cooper Philpot Retired Partner, San Francisco
Darren DeStefano Partner, Reston
Bonnie Weiss McLeod Partner, Washington, DC
Brent Siler Partner, Washington, DC
Natasha Leskovsek Partner, Washington, DC
Sandhya Deo Associate, Washington, DC
Fraser Brown Partner, Washington, DC
Mark Ballantyne Associate, Reston